source
- ai3Bio raises $48 million to develop T-helper cell-targeted immune-reset therapiesai3Bio, a new biotech startup formed from Corner Therapeutics and Novasenta, announced it has secured $48 million in an early-stage venture capital round. The company aims to create treatments for…
- Midterm elections could reshape drug pricing, Medicaid funding and research support, industry leaders warnThe November midterm elections are set to influence major health-care policy debates in Washington, according to STAT+. Industry leaders say the outcome could affect Medicaid funding levels, the p…